BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tucatinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tucatinib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05323955-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05323955)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: Secondary BRain Me
 tastases Prevention After Isolated Intracranial Progression on Trastuzumab
 /Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Fact
 or Receptor 2+ brEast Cancer With the Addition of Tucatinib\nEstimated pri
 mary completion: November 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tucatinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05323955
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800275-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05800275)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: Capecitabine\, Tuc
 atinib\, and Intrathecal Trastuzumab for Breast Cancer Patients With Lepto
 meningeal Disease\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05800275
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382364-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tucatinib: Phase 1 readout est. (NCT05382364)
DESCRIPTION:Tucatinib\, phase 1\, Colorectal Cancer.\nStudy: Safety and Pha
 rmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (
 MK-7119-002)\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05382364
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239467-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tucatinib: Phase 1 readout est. (NCT06239467)
DESCRIPTION:Tucatinib\, phase 1\, Breast Cancer.\nStudy: First-in-Human Stu
 dy of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer\nEstimat
 ed primary completion: 31 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06239467
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06016387-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tucatinib: Phase 2 readout est. (NCT06016387)
DESCRIPTION:Tucatinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Tuca
 tinib\, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy
  (XRT) in Patients With HER2+\, HER2 Mutated and/or HER2-amplified Metasta
 tic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II\, Si
 ngle Arm Feasibility Study\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06016387
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03297606-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tucatinib: Phase 2 readout est. (NCT03297606)
DESCRIPTION:Tucatinib\, phase 2.\nStudy: Canadian Profiling and Targeted Ag
 ent Utilization Trial (CAPTUR)\nEstimated primary completion: 31 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03297606
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06983691-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tucatinib: Phase na readout est. (NCT06983691)
DESCRIPTION:Tucatinib\, phase na\, Breast Cancer.\nStudy: Patient Navigatio
 n for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib\nEsti
 mated primary completion: March 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tucatinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06983691
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05673928-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05673928)
DESCRIPTION:Tucatinib\, phase 2.\nStudy: A Phase II Study of Tucatinib and 
 Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastati
 c Solid Tumors and Metastases to Brain (TUCATEMEB)\nEstimated primary comp
 letion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tucatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05673928
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05319873-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Tucatinib: Phase 1/2 readout est. (NCT05319873)
DESCRIPTION:Tucatinib\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: Ri
 bociclib\, Tucatinib\, and Trastuzumab for the Treatment of HER2 Positive 
 Breast Cancer\nEstimated primary completion: 1 April 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05319873
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05458674-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05458674)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: Tucatinib+Trastuzu
 mab+Eribulin in HER2+ MBC\nEstimated primary completion: 1 June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05458674
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05672524-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05672524)
DESCRIPTION:Tucatinib\, phase 2.\nStudy: A Study of Tucatinib and Trastuzum
 ab in People With Rectal Cancer\nEstimated primary completion: 30 July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05672524
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05748834-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05748834)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: Study of Tucatinib
  and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 P
 ositive (HER2+) Metastatic Breast Cancer\nEstimated primary completion: No
 vember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tucatini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 748834
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318389-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Tucatinib: Phase 1 readout est. (NCT07318389)
DESCRIPTION:Tucatinib\, phase 1\, Colorectal Cancer.\nStudy: ASCEND-CRC: Pr
 ofiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic
  Colorectal Cancer\nEstimated primary completion: 14 November 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07318389
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05955170-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20271219
DTEND;VALUE=DATE:20271220
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05955170)
DESCRIPTION:Tucatinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: Tuca
 tinib in Combination With Oral Etoposide andTrastuzumab in Patients With M
 etastatic HER2+ Breast Cancer\nEstimated primary completion: 19 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05955170
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494448-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tucatinib: Phase 1/2 readout est. (NCT07494448)
DESCRIPTION:Tucatinib\, phase 1/2\, Breast Cancer.\nStudy: Phase Ib/II Stud
 y of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced
  Breast Cancer\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07494448
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tucatinib: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Tucatinib\, phase 2.\nStudy: TAPUR: Testing the Use of Food and
  Drug Administration (FDA) Approved Drugs That Target a Specific Abnormali
 ty in a Tumor Gene in People With Advanced Stage Cancer\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tucatinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05253651-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tucatinib: Phase 3 readout est. (NCT05253651)
DESCRIPTION:Tucatinib\, phase 3\, Colorectal Cancer.\nStudy: A Study of Tuc
 atinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in 
 First-line HER2+ Metastatic Colorectal Cancer\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tucatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05253651
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04457596-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tucatinib: Phase 3 readout est. (NCT04457596)
DESCRIPTION:Tucatinib\, phase 3\, HER2-Positive Breast Cancer.\nStudy: T-DM
 1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People
  With High Risk HER2-Positive Breast Cancer\, the CompassHER2 RD Trial\nEs
 timated primary completion: 31 January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04457596
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05892068-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Tucatinib: Phase 2 readout est. (NCT05892068)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: A Study of Tucatin
 ib Given Before Surgery to People With HER2+ Cancers That Have Spread to t
 he Brain\nEstimated primary completion: 9 May 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05892068
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07193394-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20281207
DTEND;VALUE=DATE:20281208
SUMMARY:Tucatinib: Phase 2 readout est. (NCT07193394)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: Tucatinib and Tras
 tuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer\nEs
 timated primary completion: 7 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07193394
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06157892-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20290728
DTEND;VALUE=DATE:20290729
SUMMARY:Tucatinib: Phase 2 readout est. (NCT06157892)
DESCRIPTION:Tucatinib\, phase 2\, Breast Cancer.\nStudy: A Study of Disitam
 ab Vedotin With Other Anticancer Drugs in Solid Tumors\nEstimated primary 
 completion: 28 July 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tucatinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06157892
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439693-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Tucatinib: Phase 2 readout est. (NCT06439693)
DESCRIPTION:Tucatinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: The 
 SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Met
 astatic Breast Cancer\nEstimated primary completion: 30 March 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06439693
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Tucatinib: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Tucatinib\, phase 2\, HER2-Positive Breast Cancer.\nStudy: I-SP
 Y TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breas
 t Cancer\nEstimated primary completion: December 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tucatinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05868226-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Tucatinib: Phase 1/2 readout est. (NCT05868226)
DESCRIPTION:Tucatinib\, phase 1/2\, Colorectal Cancer.\nStudy: PRE-ISPY Pha
 se I/II Oncology Platform Program\nEstimated primary completion: 30 Decemb
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058682
 26
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07768358-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20320313
DTEND;VALUE=DATE:20320314
SUMMARY:Tucatinib: Phase 4 readout est. (NCT07768358)
DESCRIPTION:Tucatinib\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Tucat
 inib Continuation Study\nEstimated primary completion: 13 March 2032. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07768358
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686394-2271@assetmemo.bio
DTSTAMP:20261121T005834Z
DTSTART;VALUE=DATE:20320802
DTEND;VALUE=DATE:20320803
SUMMARY:Tucatinib: Phase 1/2 readout est. (NCT06686394)
DESCRIPTION:Tucatinib\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: St
 udy of Patritumab Deruxtecan With Other Anticancer Agents in Participants 
 With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically 
 Removed (MK-1022-009)\nEstimated primary completion: 2 August 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tucatinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06686394
URL:https://assetmemo.bio/drug/tucatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
